BioSyent Inc.

TSXV:RX Rapport sur les actions

Capitalisation boursière : CA$132.5m

BioSyent Résultats passés

Passé contrôle des critères 5/6

BioSyent has been growing earnings at an average annual rate of 9.3%, while the Pharmaceuticals industry saw earnings growing at 46% annually. Revenues have been growing at an average rate of 9.1% per year. BioSyent's return on equity is 20.2%, and it has net margins of 21.1%.

Informations clés

9.3%

Taux de croissance des bénéfices

13.0%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie23.1%
Taux de croissance des recettes9.1%
Rendement des fonds propres20.2%
Marge nette21.1%
Dernière mise à jour des bénéfices30 Jun 2024

Mises à jour récentes des performances passées

BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues

Mar 22
BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues

Recent updates

BioSyent's (CVE:RX) Dividend Will Be CA$0.045

Aug 30
BioSyent's (CVE:RX) Dividend Will Be CA$0.045

BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues

Mar 22
BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues

BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045

Feb 09
BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045

BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

Apr 14
BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 19
BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

Mar 17
Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Feb 18
BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

Jan 28
Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

Jan 07
BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 17
BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Dec 02
Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Ventilation des recettes et des dépenses

Comment BioSyent gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

TSXV:RX Recettes, dépenses et bénéfices (CAD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 24347190
31 Mar 24337180
31 Dec 23326180
30 Sep 23316180
30 Jun 23295170
31 Mar 23275160
31 Dec 22285160
30 Sep 22286150
30 Jun 22286140
31 Mar 22286140
31 Dec 21296140
30 Sep 21275140
30 Jun 21264150
31 Mar 21244130
31 Dec 20224120
30 Sep 20224110
30 Jun 20235110
31 Mar 20235110
31 Dec 19214100
30 Sep 19225100
30 Jun 19215100
31 Mar 19226100
31 Dec 18226100
30 Sep 18225100
30 Jun 18226100
31 Mar 18215100
31 Dec 17215100
30 Sep 1720590
30 Jun 1719590
31 Mar 1718480
31 Dec 1618480
30 Sep 1617480
30 Jun 1617480
31 Mar 1616480
31 Dec 1515470
30 Sep 1515460
30 Jun 1514460
31 Mar 1513450
31 Dec 1412350
30 Sep 1411350
30 Jun 1410350
31 Mar 149240
31 Dec 138240

Des revenus de qualité: RX has a high level of non-cash earnings.

Augmentation de la marge bénéficiaire: RX's current net profit margins (21.1%) are higher than last year (18.5%).


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: RX's earnings have grown by 9.3% per year over the past 5 years.

Accélération de la croissance: RX's earnings growth over the past year (34.6%) exceeds its 5-year average (9.3% per year).

Bénéfices par rapport au secteur d'activité: RX earnings growth over the past year (34.6%) exceeded the Pharmaceuticals industry -40.8%.


Rendement des fonds propres

ROE élevé: RX's Return on Equity (20.2%) is considered high.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé